This is why we sought to test the effects of monacolin K in NAFLD and the improvement of plasma lipid patterns observed in this study was not unexpected; especially if we consider that monacolin K acts by competitively blocking the activity of HMG-CoA reductase, the rate limiting enzymatic step in the mevalonate pathway of cholesterol synthesis. Here, HMGCR is linked to metabolic dysfunction-associated steatotic liver disease.